Physician profile
Amy Jean Wolford
NPI 1013033018
$9,069.22
in general payments reported to CMS, 2019-2025
30 companies · $2,605 in 2025
The $2,605 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,782 · 2022: $1,106 · 2023: $1,628 · 2024: $1,947 · 2025: $2,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,180.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,520.41 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $961.03 | 2021-2025 | Abilify Maintena, Rexulti, Nuedexta |
| Abbvie INC. | $910.60 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $769.20 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $589.64 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $533.66 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $397.48 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $342.54 | 2021-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $339.61 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Almatica Pharma LLC | $307.92 | 2021-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $304.82 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $270.52 | 2021-2025 | Fanapt, Hetlioz |
| Neos Therapeutics, Lp | $193.58 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Noven Therapeutics, LLC | $185.46 | 2022-2025 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $183.19 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $181.59 | 2021-2025 | Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $178.17 | 2021-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $151.83 | 2021-2023 | Aplenzin, Wellbutrin |
| Avanir Pharmaceuticals, INC. | $125.54 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $104.54 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $80.39 | 2022-2024 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $74.77 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $68.12 | 2024 | Nuplazid |
| Avadel Cns Pharmaceuticals, LLC | $66.65 | 2024-2025 | Lumryz |
| Tris Pharma INC | $66.63 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Indivior INC. | $42.75 | 2021-2022 | |
| Eisai INC. | $40.12 | 2021 | |
| Collegium Pharmaceutical, INC. | $33.49 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $30.21 | 2023 | Quviviq |
| Alfasigma USA, INC. | $14.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wolford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.